Divi’s Laboratories Q4FY22 Results: Pharma major reports over 78% profit, announces Rs 30 per share dividend

Pharma major Divi’s Laboratories on Monday reported robust earnings in the fourth quarter of the financial year 2021-22 (Q4FY22). The company registered double-digit Year-on-Year (YoY) growth on all metrics, similarly, its margin improved too during the quarter.  

As per the regulatory filing of Divi’s Lab, the consolidated profit grew by over 78 per cent to Rs 894.6 crore in Q4FY22 as compared to Rs 502 crore in the same quarter a year ago. While its consolidated revenue from operations jumped almost 41 per cent to Rs 2518.4 crore from Rs 1788.2 crore YoY. 

The company’s consolidated EBITDA (earnings before interest, taxes, depreciation, and amortization) surged over 54 per cent YoY to Rs 1104.4 crore as against Rs 716.3 crore in a year-ago quarter. And its margins improved by 370 basis points to 43.8 per cent from 40.1 per cent YoY. 

Divi's Laboratories has earned a consolidated total revenue of Rs 9074 crore for the financial year 2021-22 as against Rs 7032 crores during the previous year, reflecting a growth of 29 per cent, the company also said in its regulatory filing. 

While profit for the year amounted to Rs 2960 crore as against Rs 1984 crore for the last year, reflecting a growth of 49 per cent, it mentioned. 

“The Board of Directors of the Company has recommended a dividend of Rs 30 per share of face value Rs 2 each i.e., 1500 per cent for the financial year 2021-22, subject to the approval of members at the ensuing Annual General Meeting,” the pharma company said in release. 

During the year 2021-22, the Company has capitalised Assets valuing Rs 93456 lakh and Capital WIP as of the year-end amounted to Rs 46993 lakh, the release also mentioned.